MX2020002552A - Métodos y composiciones para preparar proteína surfactante d (sp-d). - Google Patents

Métodos y composiciones para preparar proteína surfactante d (sp-d).

Info

Publication number
MX2020002552A
MX2020002552A MX2020002552A MX2020002552A MX2020002552A MX 2020002552 A MX2020002552 A MX 2020002552A MX 2020002552 A MX2020002552 A MX 2020002552A MX 2020002552 A MX2020002552 A MX 2020002552A MX 2020002552 A MX2020002552 A MX 2020002552A
Authority
MX
Mexico
Prior art keywords
methods
compositions
surfactant protein
preparing surfactant
human
Prior art date
Application number
MX2020002552A
Other languages
English (en)
Inventor
Lars Stöckl
Jan Susan Rosenbaum
Frederick Gyapon Quast
Matthias Kaup
Original Assignee
Airway Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Airway Therapeutics Inc filed Critical Airway Therapeutics Inc
Publication of MX2020002552A publication Critical patent/MX2020002552A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
    • C12N9/003—Dihydrofolate reductase [DHFR] (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y105/00—Oxidoreductases acting on the CH-NH group of donors (1.5)
    • C12Y105/01—Oxidoreductases acting on the CH-NH group of donors (1.5) with NAD+ or NADP+ as acceptor (1.5.1)
    • C12Y105/01003—Dihydrofolate reductase (1.5.1.3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

Algunas modalidades de los métodos y composiciones proporcionadas en la presente se refieren a la preparación de proteína surfactante D (SP-D). Algunas modalidades incluyen la expresión de SP-D humana en algunas líneas celulares, y la purificación de SP-D humana a partir de estas líneas celulares. Algunas modalidades incluyen la preparación de algunas formas oligoméricas de SP-D.
MX2020002552A 2017-09-06 2018-09-04 Métodos y composiciones para preparar proteína surfactante d (sp-d). MX2020002552A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762554777P 2017-09-06 2017-09-06
US201862614774P 2018-01-08 2018-01-08
PCT/US2018/049390 WO2019050856A1 (en) 2017-09-06 2018-09-04 METHODS AND COMPOSITIONS FOR PREPARING TENSIOACTIVE PROTEIN (SP-D)

Publications (1)

Publication Number Publication Date
MX2020002552A true MX2020002552A (es) 2020-07-20

Family

ID=65518561

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002552A MX2020002552A (es) 2017-09-06 2018-09-04 Métodos y composiciones para preparar proteína surfactante d (sp-d).

Country Status (12)

Country Link
US (2) US10975389B2 (es)
EP (1) EP3679066A4 (es)
JP (1) JP2020534816A (es)
KR (1) KR20200044955A (es)
CN (1) CN111741971A (es)
AU (1) AU2018328112B2 (es)
BR (1) BR112020004540A2 (es)
CA (1) CA3074280A1 (es)
IL (1) IL272956A (es)
MX (1) MX2020002552A (es)
RU (1) RU2020109423A (es)
WO (1) WO2019050856A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019050857A1 (en) 2017-09-06 2019-03-14 Airway Therapeutics, LLC METHODS, COMPOSITIONS AND CELLS FOR PREPARING D SURFACTORY PROTEIN (SP-D)
BR112020019914A2 (pt) 2018-03-29 2021-01-05 Airway Therapeutics, Inc. Sistemas e métodos para caracterizar oligômeros de proteína surfactante d (sp-d)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030221199A1 (en) * 1998-10-20 2003-11-27 Whitsett Jeffrey A. Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
CN103627670B (zh) 2004-02-13 2016-12-21 格莱克托普有限公司 高活性糖蛋白加工条件及其有效生产方法
CA2628472C (en) * 2005-11-03 2015-01-27 Children's Hospital Medical Center Surfactant protein-d for prevention and treatment of lung infections and sepsis
NZ575974A (en) 2006-09-10 2012-03-30 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
US8471120B2 (en) 2010-05-10 2013-06-25 Monsanto Technology Llc Plants and seeds of hybrid corn variety CH419384
ES2624479T3 (es) 2010-12-21 2017-07-14 Glycotope Gmbh Métodos para cultivar células de leucemia mieloide humana y células derivadas de esta
US20120220531A1 (en) 2011-02-04 2012-08-30 Cincinnati Children's Hospital Medical Center Surfactant protein d for the treatment of disorders associated with lung injury
CA2897505A1 (en) * 2013-01-18 2014-07-24 Glycotope Gmbh Peptides for enhancing protein expression
EP2829612A1 (en) * 2013-07-25 2015-01-28 Technische Universität München Method for producing exopolysaccharides, products and uses thereof
NL2011626C2 (en) * 2013-10-17 2015-04-20 Stichting Tech Wetenschapp Novel polypeptide and uses thereof.
HRP20211710T1 (hr) 2014-05-22 2022-02-04 Byondis B.V. Konjugacija specifična za mjesto spajanja lijekova za povezivanje s protutijelima i konjugati protutijela u lijeku koji nastaje kao rezultat
ES2753259T3 (es) 2015-04-22 2020-04-07 Curevac Ag Composición que contiene ARN para el tratamiento de enfermedades tumorales
WO2017162733A1 (en) 2016-03-22 2017-09-28 Glycotope Gmbh Iga antibodies with enhanced stability
WO2019050857A1 (en) 2017-09-06 2019-03-14 Airway Therapeutics, LLC METHODS, COMPOSITIONS AND CELLS FOR PREPARING D SURFACTORY PROTEIN (SP-D)

Also Published As

Publication number Publication date
CA3074280A1 (en) 2019-03-14
US20220042036A1 (en) 2022-02-10
BR112020004540A2 (pt) 2020-09-08
AU2018328112B2 (en) 2023-08-24
RU2020109423A (ru) 2021-10-06
US20190071694A1 (en) 2019-03-07
WO2019050856A1 (en) 2019-03-14
KR20200044955A (ko) 2020-04-29
US10975389B2 (en) 2021-04-13
RU2020109423A3 (es) 2022-02-16
EP3679066A4 (en) 2021-06-09
CN111741971A (zh) 2020-10-02
IL272956A (en) 2020-04-30
EP3679066A1 (en) 2020-07-15
AU2018328112A1 (en) 2020-03-19
JP2020534816A (ja) 2020-12-03

Similar Documents

Publication Publication Date Title
MX2023011785A (es) Metodos y composiciones para produccion de proteina de clara de huevo.
MX2022012374A (es) Composiciones multi-suplementos.
MX2020006117A (es) Integracion dirigida de acidos nucleicos.
MX2019002904A (es) Composiciones de arn de alta pureza y métodos para su preparación.
NZ730803A (en) Methods for the preparation of ribosides
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
MX2016012479A (es) Miembros de unión al factor de necrosis tumoral (tnf) alfa.
MX2017009720A (es) Composiciones de oligosacaridos para el uso en composiciones nutricionales y metodos para producirlas.
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
MX2018011162A (es) Metodos de purificacion de colageno 7.
MX2024001617A (es) Composiciones biofarmaceuticas.
MX2020007945A (es) Proteinas f del rsv estabilizadas y usos de las mismas.
MX2016014147A (es) Composiciones de proteina soluble y metodos para su elaboracion.
PH12017501070A1 (en) Peptides and their use in the treatment of skin
MX2019002924A (es) Composiciones purificadas de oligosacaridos de leche humana.
MX2017013855A (es) Metodo para la separacion de proteina y otras impurezas de polisacaridos capsulares microbianos.
MX2016014144A (es) Composiciones de proteina concentrada y metodos para su elaboracion y uso.
EP4275746A3 (en) Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use
PH12016501689B1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
WO2015123493A3 (en) Compositions and methods for modulatuion of immune response
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
MX2021006458A (es) Pared celular de levadura enriquecida en proteina de manano-oligosacarido.
WO2018132821A3 (en) Elastomeric proteins
MX2020002552A (es) Métodos y composiciones para preparar proteína surfactante d (sp-d).
MX2020002551A (es) Metodos, composiciones y celulas para preparar proteina surfactante d (sp-d).